



Prescription Pharmaceutical Products¹

PRODUCT	INDICATION	TERRITORY					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
Oncology/Hematology							
Minjuvi®	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	—	Q1-24	Submitted	Submitted	Approved	Incyte
Pemazyre®	Metastatic cholangiocarcinoma	—	Submitted	Submitted	Submitted	Submitted	Incyte
Akynzeo®	Prevention of chemotherapy-induced acute and delayed nausea and vomiting	Q4-22	Q3-22	Q3-22	—	—	Helsinn
Aloxi®	Prevention of acute nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy	Q4-22	—	—	—	—	Helsinn
Tavalisse®	Treatment of chronic immune thrombocytopenia	—	Submitted	Pre-registration	Submitted	Submitted	Rigel
Trelstar®	Advanced prostate cancer	Q2-20	—	—	—	—	Debiopharm
Vidaza®	Myelodysplastic syndrome	—	Q2-10	—	—	—	BMS
Abraxane®	Metastatic pancreatic cancer	—	Q4-17	—	—	—	BMS
Halaven®	Metastatic breast cancer and soft tissue sarcoma	—	Q4-17	Q4-19	Q2-22	—	Eisai
Lenvima®	Differentiated thyroid cancer and unresectable hepatocellular carcinoma	—	Q4-17	—	Q1-22	—	Eisai
Lenvima®	Advanced renal cell cancer	—	Q4-17	—	—	—	Eisai
BGx							
Ladevina® (lenalidomide)	Multiple myeloma; myelodysplastic syndrome	—	—	2011	Q3-19	—	Own
Ladevina® (lenalidomide)	Mantle Cell Lymphoma; follicular lymphoma	—	—	2011	—	—	Own
Zyvalix® (abiraterone)	Metastatic prostate cancer	—	—	2014	Q2-18	—	Own
Karfib® (carfilzomib)	Relapsed or refractory multiple myeloma	—	—	Q4-19	Approved	—	Own
Leprid® (leuprolide)	Palliative treatment of advanced prostate cancer	—	—	2007	—	—	Own
Rembre® (dasatinib)	Chronic myeloid leukemia	—	—	2013	Q1-22	—	Own
Palbocil®, Bapocil® (palbociclib)	Breast cancer	—	—	Q1-23	Submitted	—	Own
Xetrane® (pomalidomide)	Multiple myeloma	—	—	Q2-19	Submitted	—	Own
Xetrane® (pomalidomide)	AIDS-related Kaposi sarcoma	—	—	Q2-22	—	—	Own

¹ See MD&A for more details.



PRODUCT	INDICATION	TERRITORY					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
Infectious Diseases							
Ambisome®	Invasive fungal infection	—	1997	—	—	—	Gilead
Cresemba®	Invasive fungal infection	—	Q2-20	Q3-19	Q3-19	Q2-19	Basilea
Impavido®	Leishmaniasis						Own
BGx							
Dolufevir® (dolutegravir)	HIV infection			Q2-21			Own
Other Specialty							
Exelon®	Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease	Q2-21	Q2-21	Q2-21	Q2-21	Q2-21	Own
Ibsrela®	IBS-C	Q1-21	—	—	—	—	Ardelyx
Salofalk®	Ulcerative colitis	—	—	2007	Pre-2019	—	Dr. Falk
Ursofalk®	Primary biliary cirrhosis	—	—	2007	Pre-2019	—	Dr. Falk
Imvexxy®	Moderate-to-severe dyspareunia	Q1-24	—	—	—	—	TXMD
Bijuva®	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24	—	—	—	—	TXMD
BGx							
Fibridoner® (pirfenidone)	Idiopathic pulmonary fibrosis			2017			Own

¹ See MD&A for more details.



Pipeline and Products in Early Launch Stage¹

The Company expects that its pipeline and products in early launch stage could achieve total revenues of over \$150,000,000 combined in their peak years. The products in early launch stage are within three years from the commercial launch date on a country by country basis.

PRODUCT	INDICATION OR THERAPEUTIC AREA	TERRITORY					LAUNCH / EXPECTED LAUNCH YEAR
		Canada	Brazil	Argentina	Colombia	Mexico	
Oncology/Hematology							
Minjuvi [®]	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	—	Q1-24	Submitted	Submitted	Approved	2025 -2026
Pemazyre [®]	Metastatic cholangiocarcinoma	—	Submitted	Submitted	Submitted	Submitted	2025-2026
Tavalisse [®]	Treatment of chronic immune thrombocytopenia	—	Submitted	Pre-registration	Submitted	Submitted	2025-2026
Bapocil [®]	Breast Cancer				Submitted		2025
Xetrane [®]	Multiple myeloma				Submitted		2025
Rembre [®]	Chronic myeloid leukemia				Q1-22		—
O501	Oncology/Hematology			Submitted			2025
O502	Oncology/Hematology			Submitted			2025
H402	Oncology/Hematology		Development		Development		2028-2029
Other Specialty							
Invexxy [®]	Moderate-to-severe dyspareunia	Q1-24	—	—	—	—	—
Bijuva [®]	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24	—	—	—	—	—
IPX203	Parkinson's disease	Pre-registration	Pre-registration	Pre-registration	Pre-registration	Pre-registration	2027-2028
Qelbree [™]	Attention-Deficit Hyperactivity Disorder (ADHD)	Pre-registration	—	—	—	—	2026-2027
Jornay PM [™]	Attention-Deficit Hyperactivity Disorder (ADHD)	Submitted	Pre-registration			Pre-registration	2025-2028
C401 (Neurology)	Other Specialty				Submitted	—	2025-2026
C402/403 (Neurology)	Other Specialty	—	Submitted		Development	Pre-registration	2026-2027

¹ See MD&A for more details.